Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

In CF, Arcturus is advancing an inhalable mRNA therapy, ARCT-032, for which it is running a Phase II trial in patients who ...

The bright constellations of winter have departed in the west, while the stars of spring are climbing the eastern and ...

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 67.09% and 3.10%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Neda Safarzadeh Safarzadeh; Vice President and Head of Investor Relations, Public Relations and Marketing; Arcturus Therapeutics Holdings Inc. Joseph Payne; Presiden ...

As the Army looks to do away with its current pursuit of a future tactical drone, the plan to fill the mission is murky.

SAN DIEGO (AP) — SAN DIEGO (AP) — Arcturus Therapeutics (ARCT) on Monday reported a loss of $14.1 million in its first quarter. On a per-share basis, the San Diego-based company said it had a loss of ...

During the last three months, 7 analysts shared their evaluations of Arcturus Therapeutics (NASDAQ:ARCT), revealing diverse outlooks from bullish to bearish. The following table summarizes their ...

Payne reported the recent EU approval of KOSTAIVE, Arcturus' self-amplifying mRNA COVID-19 vaccine, and receipt of an initial milestone payment from CSL. He announced an upcoming marketing ...

Sometime soon, astronomers are expected a star over 3000 lightyears away to go nova any time now. When it does this star will ...

The Coma Cluster is a rich group of galaxies visible in Coma Berenices, high in the southern sky late this evening.